Protein Kinase Inhibitors: all 15,278 studies that test it

Page 102 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.

• A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian CancerCompletedNCT03695380Phase 1
• Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping MutationStatus unknownNCT03693339Phase 2
• A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast CancerActive, not recruitingNCT03691051Phase 2
• A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AMLTerminatedNCT03690154Phase 1
• Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (allo-SCT) in FLT3-ITD AML PatientsCompletedNCT03690115Phase 2
• Study of Imatinib in Children With Neurofibromatosis and Airway TumorsWithdrawnNCT03688568Phase 2
• Study of Sirolimus in CTD-TP in ChinaStatus unknownNCT03688191Phase 4
• A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell LymphomaCompletedNCT03688152Phase 1
• Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor LeukemiaTerminatedNCT03686345Phase 2
• ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)CompletedNCT03685448Phase 2
• HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast CancerCompletedNCT03685331Phase 1
• Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLCWithdrawnNCT03684967Phase 2
• Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid TumorsActive, not recruitingNCT03682289Phase 2
• RO5126766 for Patients With Advanced KRAS-Mutant Lung CancerCompletedNCT03681483Phase 1
• Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm DysfunctionActive, not recruitingNCT03681275Phase 2
• 9-ING-41 in Patients With Advanced CancersActive, not recruitingNCT03678883Phase 2
• A Phase II Study in Patients With Moderate to Severe Active Crohn's DiseaseCompletedNCT03677648Phase 2
• Imatinib for Multiple Sclerosis (MS) RelapsesStatus unknownNCT03674099Phase 2
• Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)Active, not recruitingNCT03674047Phase 2
• A Trial of Ipatasertib in Combination With AtezolizumabActive, not recruitingNCT03673787Phase 1/2
• Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC PatientsStatus unknownNCT03672136Phase 2
• Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell MalignanciesTerminatedNCT03671590Phase 1
• Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and CisplatinStatus unknownNCT03671538Not applicable
• Itacitinib in Treating Patients With Refractory Metastatic/Advanced SarcomasTerminatedNCT03670069Phase 1
• AZD6738 & Gemcitabine as Combination TherapyStatus unknownNCT03669601Phase 1
• Safety, Tolerability and PK/PD of SHR1459 in Healthy VolunteersStatus unknownNCT03668509Phase 1
• AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine CarcinosarcomaActive, not recruitingNCT03668340Phase 2
• Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLCActive, not recruitingNCT03667820Phase 2
• Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell CancerCompletedNCT03667482Phase 1
• Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-PaclitaxelStatus unknownNCT03666832Phase 1/2
• Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell NeoplasmstumorStatus unknownNCT03664297Phase 1
• A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female SubjectsCompletedNCT03662516Phase 1
• Study of Sirolimus in Patients With Advanced Pancreatic CancerStatus unknownNCT03662412Phase 1/2
• Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic CancerStatus unknownNCT03662035Phase 2
• A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic DermatitisCompletedNCT03661138Phase 3
• SRC Inhibition as a Potential Target for Parkinson's Disease PsychosisStatus unknownNCT03661125Early Phase 1
• Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant TumorsCompletedNCT03660761Phase 2
• An Investigational Study of Experimental Medication BMS-986165 in Healthy ParticipantsCompletedNCT03660436Phase 1
• A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)CompletedNCT03660059Phase 3
• Impact of Ursodeoxycholic Acid, Silymarin, Antioxidants and Colchicine on Fibrosis Regression in HCV After SVRCompletedNCT03659058Not applicable
• A Study of XY0206 in Subjects With Advanced or Metastatic Solid TumoursStatus unknownNCT03658070Phase 1
• Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple MyelomaWithdrawnNCT03657420Phase 1
• A Study to Evaluate the PF-06700841 Effect on QTc Interval in Healthy VolunteersCompletedNCT03656952Phase 1
• To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung AdenocarcinomaStatus unknownNCT03656393Phase 3
• Apatinib Combined With S-1 for the Treatment of Recurrent/Metastatic Head and Neck MalignanciesStatus unknownNCT03654612Phase 1/2
• Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast CancerCompletedNCT03654547Phase 1
• Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLCStatus unknownNCT03654027Phase 2
• First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) MetastasesCompletedNCT03653546Phase 2/3
• Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckWithdrawnNCT03652233Phase 1
• Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung CancerStatus unknownNCT03651219Phase 3
• This Study Was a Prospective, One-arm Open Phase II Clinical Trial. A Systematic Review of the pCR of Apatinib in Combination With the Albumin Paclitaxel and Carboplatin Regimens for the Neoadjuvant Therapy of Triple-negative Breast Cancer, as Well as the Safety of TreatmentStatus unknownNCT03650738Phase 2
• Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)CompletedNCT03648489Phase 2
• A Study to Determine the Effects of PF-04965842 on Midazolam PK in Healthy VolunteersCompletedNCT03647670Phase 1
• A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic DermatitisCompletedNCT03646604Phase 1
• ABI-009 (Nab-rapamycin) for Surgically-Refractory Epilepsy (RaSuRE)CompletedNCT03646240Phase 1
• Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF)Active, not recruitingNCT03645824Phase 2
• Treatment of Carrying TP53 Harmful MutationsStatus unknownNCT03645200Phase 1
• Study of ICP-105 in Solid Tumors PatientsCompletedNCT03642834Phase 1
• Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AMLStatus unknownNCT03642236Phase 2/3
• The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid TumorCompletedNCT03641586Phase 1
• Phase 1 Study to Evaluate ASN002 Absorption, Metabolism, and Excretion of [14C] Following a Single Oral Dose in Healthy Male SubjectsCompletedNCT03641573Phase 1
• Imatinib in Acute Ischaemic StrokeStatus unknownNCT03639922Phase 3
• A Safety and Efficacy Study to Evaluate AIV001 in Wound Healing Following Surgical IncisionCompletedNCT03639883Phase 1/2
• Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal CarcinomaStatus unknownNCT03639467Phase 1/2
• Drug Interaction Study Evaluating the Effect of Rifampin on PK and Safety of PF 04965842.CompletedNCT03637790Phase 1
• A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell CarcinomaActive, not recruitingNCT03635892Phase 2
• A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)Active, not recruitingNCT03634540Phase 2
• Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842.CompletedNCT03634345Phase 1
• A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR MutationsStatus unknownNCT03634059Not applicable
• A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With GliomasWithdrawnNCT03632317Phase 2
• CLN-0046: Treatment of AMD Subjects With OTX-TKICompletedNCT03630315Phase 1
• Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin AnalogueStatus unknownNCT03629847Phase 1/2
• Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast CancerCompletedNCT03628066Phase 2
• Study Maintenance Regorafenib vs Placebo, no Progression Patients After I Line Chemotherapy Metastatic Gastric CancerCompletedNCT03627728Phase 2
• A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion of [14C]SulfatinibCompletedNCT03627520Early Phase 1
• A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative ColitisWithdrawnNCT03627052Phase 2
• A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid LeukemiaCompletedNCT03625505Phase 1
• Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaCompletedNCT03625388Phase 2
• CFI-400945 in Patients With Advanced/Metastatic Breast CancerActive, not recruitingNCT03624543Phase 2
• Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung CancerStatus unknownNCT03624309Phase 2
• Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3-ITDCompletedNCT03622541Phase 2
• Efficacy of First Line B-RI for Treatment Naive Waldenström's MacroglobulinemiaActive, not recruitingNCT03620903Phase 2
• Trial of eRapa in Prostate Cancer PatientsCompletedNCT03618355Phase 1
• Anlotinib for Advanced and Refractory Natural Killer /T-cell LymphomaCompletedNCT03618238Phase 2
• Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell LymphomaWithdrawnNCT03617484Phase 2
• Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor TherapyCompletedNCT03616834Phase 2
• Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.Active, not recruitingNCT03616587Phase 1
• Ruxolitinib Plus LVP in Patients With R/R ETP-ALLStatus unknownNCT03613428Phase 1/2
• Adjuvant Treatment of Apatinib in Nasopharyngeal CarcinomaStatus unknownNCT03612219Phase 2
• Study of Lorlatinib in ROS1 Rearranged NSCLCStatus unknownNCT03612154Phase 2
• Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLCActive, not recruitingNCT03611738Phase 1
• Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid TumorsCompletedNCT03611595Phase 1
• Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase InhibitorsActive, not recruitingNCT03610971Phase 2
• A Study to Investigate Apatinib Combined Capecitabine on Adjuvant Therapy of Biliary CarcinomaStatus unknownNCT03609489Phase 2
• PDR001 Plus Imatinib for Metastatic or Unresectable GISTCompletedNCT03609424Phase 1/2
• Adjuvant Palbociclib in Elderly Patients With Breast CancerActive, not recruitingNCT03609047Phase 2
• A STUDY TO ESTIMATE THE EFFECT OF PF-06651600 ON THE PHARMACOKINETICS (PK) OF ORAL CONTRACEPTIVE (OC)CompletedNCT03608241Phase 1
• X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene RearrangementStatus unknownNCT03608007Phase 2
• A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-64264681 in Healthy Male and Female ParticipantsCompletedNCT03607513Phase 1
• Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA)CompletedNCT03606590Phase 2

← Protein Kinase Inhibitors overview